A new chapter in ALS drug development: How smarter trials and precision medicine are accelerating hope

Navigate the future of ALS trials with the right partner.

Amyotrophic lateral sclerosis (ALS) drug development has reached a moment where scientific promise and clinical urgency are colliding. For patients whose eligibility can disappear in weeks, the difference between progress and delay is profound. At the same time, advances in precision medicine and gene-based therapies are beginning to reshape what is possible in ALS research, offering new strategies for developers who have the tools and expertise to navigate this evolving landscape. 

However, scientific optimism comes with operational realities. Sponsors must navigate fierce competition at established ALS centers, manage substantial patient and caregiver burden, and execute studies quickly enough to enroll patients before disease progression limits eligibility. These pressures demand coordinated, expert-driven trial strategies. To meet this moment, trial strategies must evolve. With the right expertise, infrastructure, and cross-functional support, sponsors are able to design ALS studies that move faster, reduce burden, and generate more meaningful clinical outcomes — accelerating progress for patients who urgently need it.

Understanding the realities of ALS

Designing ALS trials requires a clear understanding of the lived patient experience and the clinical challenges of the disease. ALS patients experience complex and highly variable progression alongside significant emotional impact, and these realities should influence every aspect of study design and operational planning. 

The emotional and clinical weight of an ALS diagnosis

An ALS diagnosis can be life-changing for patients and families. Many describe it as one of the most difficult moments of their lives, not only because of the physical challenges that lie ahead but also because of the lack of disease modifying therapies available that are able to revert its course. The way this news is communicated, and the support provided in those early moments, may also influence how patients cope and whether they are open to exploring clinical trial options. 

Additionally, reaching a confirmed diagnosis often takes much longer than people expect. Patients may wait several months while symptoms evolve and other conditions are ruled out. This prolonged period can leave families balancing fear, unanswered questions, and concerns about whether trial opportunities will still be available once a diagnosis is finalized. These delays often have real consequences for enrollment, especially when early participation is key to capturing meaningful clinical change. 

The often-overlooked burden on caregivers

ALS places considerable demands on caregivers, whose support is essential both at home and throughout the trial process. Caregivers often manage scheduling, documentation, transportation, and symptom tracking, and these responsibilities intensify as the disease advances. The emotional toll is often even greater than the physical work. Trying to stay hopeful while witnessing daily decline can be exhausting, and tasks such as medication logging or preparing for study visits can take meaningful time away from simply being together. For families who live farther from trial sites, travel adds another layer of strain.  

A disease with dramatically variable progression

ALS progression varies greatly between individuals. Some patients experience changes over a short period of time, while others follow a more gradual trajectory. This variability creates challenges for families trying to understand what lies ahead and for trial teams attempting to plan around shifting eligibility and clinical needs. Bulbar involvement, which affects speech, swallowing, and communication, is a particularly stark example of how profoundly ALS can reshape daily functioning. These changes also highlight the difficulty of measuring ALS consistently in a clinical study. Symptoms may emerge or progress at different times, making it hard to rely on endpoints that assume a uniform pattern of change. For trial teams, accounting for this unpredictability is essential when designing studies that aim to capture meaningful clinical outcomes. 

Major challenges in ALS clinical trials

Clinical development in ALS is shaped as much by operational realities as by scientific rigor. Sponsors face various constraints that influence recruitment, site selection, patient experience, and ultimately the success of the study. Addressing these challenges early is essential for building feasible and patient-centered ALS protocols. 

1. Competing for experienced sites

ALS trials often depend on a small group of highly experienced centers, but these sites are frequently saturated with studies, creating competition for both patients and site resources that may slow enrollment. Although expanding into less-frequented regions could increase access to newly diagnosed individuals, sponsors often hesitate because supportive care, diagnostic practices, or genetic backgrounds may differ across countries. These variations introduce additional planning considerations and are often difficult to navigate without the right resources and expertise.  

2. Enabling speed where it counts 

Because ALS can progress unpredictably — with some patients experiencing drastic changes in a relatively short period of time — even small operational delays can cause patients to lose eligibility within weeks. Timing affects every step of a study, including site activation, contracting, drug supply, and screening, and sponsors must be prepared to move efficiently to keep pace with the disease. 

3. Building trials that adequately center patients and caregivers

In ALS trials, supporting patients and caregivers is not just a patient-centric concern but a critical operational challenge for sponsors. As disease progression affects mobility, communication, and stamina, caregiver involvement often increases quickly, creating evolving support needs that are often difficult to anticipate and scale. Sponsors may lack the infrastructure or flexibility to address these demands early and consistently across sites, particularly in global studies. When patient and caregiver support is not adequately planned or implemented in real time, burden increases. This frequently affects retention, protocol adherence and overall trial feasibility.  

The rise of precision medicine 

Precision medicine is beginning to transform ALS drug development. Because ALS varies widely in its biological underpinnings and clinical presentation, understanding each patient’s unique disease drivers is increasingly important for developing and evaluating targeted therapies. Gene-directed approaches are accelerating this shift and demonstrating the potential for more individualized treatment strategies.  

Precision medicine has the potential to:  

• Identify the biological mechanisms contributing to disease
• Improve diagnostic confidence and reduce time to achieve diagnosis
• Match patients with therapies that align with their underlying biology
• Better address the heterogeneity that complicates traditional trial design  

A central component of precision medicine in ALS is deeper patient profiling. Clinical, genetic, and progression-related data aid in determining when a patient should enter a study and which investigational therapy is best aligned with their biology. Although clinicians still cannot predict individual disease trajectories with full accuracy, these insights support more informed enrollment decisions and enable sponsors to design trials that reflect the true diversity of ALS progression. Early biomarker and genetic modifier research adds further clarity, and as datasets continue to grow, developers will be better positioned to refine eligibility criteria and target therapies more precisely. For sponsors, this also means rethinking eligibility criteria, site readiness, and startup timelines to align with biomarker identification. 

Realizing the full potential of precision medicine also requires strong collaboration across industry and academia. Academic centers often drive foundational biological discovery, while industry partners provide the infrastructure, operational expertise, and regulatory expertise needed to translate these insights into real-world trials. This combined effort is creating a clearer route toward more individualized and meaningful ALS therapies. 

Setting up ALS trials for success

As ALS drug development advances, trials require proactive planning, patient-centered design, and partners who understand both the clinical realities of the disease and the operational urgency involved. Translating scientific progress into real-world trials requires deliberate operational choices. There are several strategic approaches that allow sponsors to do this while accelerating timelines, improving feasibility and better supporting patients. 

Expand and diversify your geographic footprint 

With many ALS trials relying heavily on a small group of high-performing centers, competition increases and enrollment slows. Engaging additional regions has the potential to expand access to newly diagnosed patients and improve recruitment speed, provided diagnostic capabilities and supportive care are sufficient. A global CRO partner should be able to evaluate country-level feasibility, assess variations in standard of care, and build a balanced site network that supports faster enrollment and more representative clinical data. 

Keep the patients and caregivers front-of-mind

Building ALS trials around patients and caregivers requires experience, infrastructure, and the ability to operationalize patient-centric strategies early and consistently. When these considerations are addressed proactively, studies are better positioned to maintain retention, protect data quality and deliver a more sustainable trial experience. 

High-impact approaches include:  

• Transportation support and concierge services that simplify visit logistics
• Visit schedules that consider fatigue, mobility limitations and communication needs 
• Home-based or remote services whenever possible to preserve energy and time together
• Digital tools such as telehealth, remote monitoring, and e-consent to reduce travel and administrative burden
• Planning proactively for increased support needs as caregivers take on more responsibilities over time  

Implementing these strategies requires partners with proven experience in ALS and rare disease trials, as well as the operational flexibility to adjust support as patient needs evolve.

Move quickly with teams who understand ALS urgency 

Speed is critical in ALS trials. Delays in activation, contracting, drug supply or enrollment can result in patients losing eligibility within weeks. Effective planning relies on operational models that support rapid escalation, streamlined communication and fast decision-making. Teams who understand ALS urgency are better able to anticipate barriers before they arise and maintain momentum through critical trial milestones. 

Leverage deep therapeutic and operational expertise 

ALS studies benefit from teams with specialized insight into disease progression, symptom variability and clinical priorities. Experienced project leaders, clinical scientists, and medical experts are able to refine feasibility, optimize endpoint strategies, and strengthen patient-profiling approaches. This expertise is especially important as ALS development moves toward more targeted and biologically informed therapies. Teams who understand both the clinical realities of ALS and the operational implications of precision medicine approaches are better equipped to design trials that remain scientifically grounded, patient-focused, and prepared for the next generation of ALS treatment strategies.  

Why choose the PPD™ clinical research business of Thermo Fisher Scientific 

The PPD™ clinical research business of Thermo Fisher Scientific offers the specialized expertise and operational strength necessary to support the complexity of ALS development. Our teams have led more than 70 rare  neuromuscular studies in recent years and possess a deep understanding of ALS progression, trial design, and patient needs. Through our dedicated neuroscience and rare disease pillars, supported by the Rare Disease Center of Excellence, we provide strategic, cross-functional guidance that enables sponsors to navigate today’s challenges while preparing for what is ahead.  

As ALS drug development evolves, precision medicine will play an increasingly important role. Our position within Thermo Fisher Scientific gives us access to the laboratory services, genetic analysis capabilities, and advanced data tools needed to support more individualized and biologically informed development strategies. When combined with our responsive operational model, our capabilities create a strong foundation for sponsors looking to advance next-generation ALS therapies.  

Our patient-first framework further supports study success by reducing burden and improving retention. Key services include transportation and concierge support, visit schedules designed around the patient, decentralized and home-based options when appropriate, and digital tools that enable patients to remain engaged as mobility declines. Our coordinated startup and drug supply processes also enable enrollment to occur at the right time.  

With these capabilities, we are ready to support the next generation of ALS drug development, including precision medicine approaches, and advance new therapies with efficiency and compassion.